TFX Quote, Financials, Valuation and Earnings

Glaukos has a net margin of 14.52% compared to Teleflex's net margin of -22.15%. Teleflex's return on equity of 5.32% beat Glaukos's return on equity of -27.46%.

Teleflex has a consensus price target of $238.68, signalling upside risk potential of 33.9%. On the other hand Glaukos has an analysts' consensus of -- which suggests that it could fall by -0.75%. Given that Teleflex has higher upside potential than Glaukos, analysts believe Teleflex is more attractive than Glaukos.

Teleflex has a beta of 1.156, which suggesting that the stock is 15.641% more volatile than S&P 500. In comparison Glaukos has a beta of 1.034, suggesting its more volatile than the S&P 500 by 3.395%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. Glaukos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. Glaukos pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than Glaukos quarterly revenues of $96.7M. Teleflex's net income of $111M is higher than Glaukos's net income of -$21.4M. Notably, Teleflex's price-to-earnings ratio is 35.44x while Glaukos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.78x versus 21.02x for Glaukos. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 14.52% compared to Teleflex's net margin of 8.28%. Teleflex's return on equity of 5.32% beat Globus Medical's return on equity of 2.27%.

Teleflex has a consensus price target of $238.68, signalling upside risk potential of 33.9%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.39%. Given that Teleflex has higher upside potential than Globus Medical, analysts believe Teleflex is more attractive than Globus Medical.

Teleflex has a beta of 1.156, which suggesting that the stock is 15.641% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than Globus Medical quarterly revenues of $625.7M. Teleflex's net income of $111M is higher than Globus Medical's net income of $51.8M. Notably, Teleflex's price-to-earnings ratio is 35.44x while Globus Medical's PE ratio is 124.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.78x versus 4.60x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of 14.52% compared to Teleflex's net margin of -35.93%. Teleflex's return on equity of 5.32% beat PROCEPT BioRobotics's return on equity of -37.42%.

Teleflex has a consensus price target of $238.68, signalling upside risk potential of 33.9%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $102.75 which suggests that it could grow by 26.62%. Given that Teleflex has higher upside potential than PROCEPT BioRobotics, analysts believe Teleflex is more attractive than PROCEPT BioRobotics.

Teleflex has a beta of 1.156, which suggesting that the stock is 15.641% more volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than PROCEPT BioRobotics quarterly revenues of $58.4M. Teleflex's net income of $111M is higher than PROCEPT BioRobotics's net income of -$21M. Notably, Teleflex's price-to-earnings ratio is 35.44x while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.78x versus 20.84x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

QuidelOrtho has a net margin of 14.52% compared to Teleflex's net margin of -2.74%. Teleflex's return on equity of 5.32% beat QuidelOrtho's return on equity of -47.52%.

Teleflex has a consensus price target of $238.68, signalling upside risk potential of 33.9%. On the other hand QuidelOrtho has an analysts' consensus of -- which suggests that it could grow by 14.52%. Given that Teleflex has higher upside potential than QuidelOrtho, analysts believe Teleflex is more attractive than QuidelOrtho.

Teleflex has a beta of 1.156, which suggesting that the stock is 15.641% more volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.107, suggesting its less volatile than the S&P 500 by 89.318%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than QuidelOrtho quarterly revenues of $727.1M. Teleflex's net income of $111M is higher than QuidelOrtho's net income of -$19.9M. Notably, Teleflex's price-to-earnings ratio is 35.44x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.78x versus 1.06x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.